AstraZeneca to highlight the breadth of its respiratory medicines at American Thoracic Society 2016 International Conference

New data reflect advancements across novel inhaled therapies, respiratory biologics and research into underlying disease pathways

12 May 2016

AstraZeneca will demonstrate the breadth and depth of its industry-leading respiratory disease medicines with more than 60 abstracts and scientific presentations at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, California, 13-18 May 2016.

Data support AstraZeneca’s novel inhaled combinations, respiratory biologics and innovative science, which targets new pathways in asthma and chronic obstructive pulmonary disease (COPD). Highlights include:

  • 14 abstracts focused on unmet need in COPD as well as Bevespi Aerosphere (glycopyrrolate/formoterol fumarate),recently approved by the US FDA, a novel fixed-dose dual bronchodilator pMDI utilising the latest co-suspension technology for the treatment of COPD, including 24-hour lung function data compared to tiotropium bromide inhalation spray and placebo.
  • Biomarker data on benralizumab, an anti–eosinophil monoclonal antibody currently in Phase III trials in both severe asthma and COPD. The data evaluate the potential for high baseline blood eosinophils as well as baseline serum biomarkers of the IL-13 pathway to predict treatment response. These data may be of value for both benralizumab and tralokinumab (IL-13 monoclonal antibody).
  • Data highlighting breakthrough science aimed at addressing and potentially modifying the underlying causes of respiratory diseases, with a research focus on four key biological pathways: eosinophilic disease, Th2-driven disease, epithelial-driven pathobiology and autoimmunity.

In addition, data will be presented evaluating the effects on lung function and airway inflammation of Daxas (roflumilast), the oral PDE4 inhibitor, initiated in addition to standard therapy with corticosteroids and antibiotics at the onset of an acute exacerbation of COPD.

Tom Keith-Roach, Vice President, Global Product Strategy for Respiratory, Inflammation and Autoimmunity, said: “Respiratory is one of AstraZeneca’s main therapy areas and it’s exciting that the data being shared at ATS demonstrate how rapidly our pipeline and portfolio are developing. We believe Bevespi Aerosphere and investigational medicines such as benralizumab can make a real difference in the lives of patients living with respiratory conditions worldwide.”

AstraZeneca/MedImmune key presentations at ATS 2016

 

Lead author

Abstract title

Presentation details

COPD, Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) and PT010 (budesonide/glycopyrrolate/formoterol)

 

Ding B


A cross-sectional assessment of the burden of chronic obstructive pulmonary disease (COPD) symptoms in the United States and Europe using the National Health and Wellness Survey

Oral Tuesday, 17 May, 3:00 PM Abstract #A6156

PINNACLE-1 &

PINNACLE-2

Martinez F

Pooled analyses from PINNACLE-1 and -2; the novel LAMA/LABA co-suspension technology glycopyrrolate/formoterol fixed-dose combination delivered by MDI shows significant improvement versus monocomponents in patients with COPD

Wednesday, 18 May, 9:00 AM Abstract #A6782

PINNACLE-3

Hanania N

Safety and efficacy of a novel LAMA/LABA co-suspension technology glycopyrrolate/formoterol fixed-dose combination delivered by MDI: Results of a one-year extension study in patients with COPD (PINNACLE-3)

Wednesday, 18 May, 9:00 AM Abstract #A6791

Arora S

24-hour lung function profile of novel co-suspension glycopyrrolate/formoterol metered dose inhaler versus placebo and Spiriva® Respimat®, in patients with moderate-to-very-severe chronic obstructive pulmonary disease

Wednesday, 18 May, 9:00 AM Abstract #A6823

Arora S

24-hour lung function following the novel LAMA/LABA co-suspension technology of glycopyrrolate/formoterol fixed-dose combination MDI, in patients with moderate-to-very-severe COPD

Wednesday, 18 May, 9:00 AM Abstract #A6792

Martinez F

The novel LAMA/LABA co-suspension technology of glycopyrrolate/formoterol fixed-dose combination MDI significantly improves health status in symptomatic patients with COPD

Wednesday, 18 May, 9:00 AM Abstract #A6784

Mack P

Drug delivery from a novel LAMA/LABA co-suspension technology of glycopyrrolate/formoterol fixed-dose combination MDI: Evidence of consistency, robustness and patient-use reliability

Tuesday, 17 May, 9:00 AM Abstract #A5839

Orevillo C

Pharmacokinetic and safety profile of a novel co-suspension technology fixed-dose combination of budesonide/glycopyrrolate/formoterol delivered by metered dose inhaler (PT010) in healthy adult subjects

Wednesday, 18 May, 9:00 AM Abstract #6827

SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

 

Inoue H

Proportion and characteristics of asthma– chronic obstructive pulmonary disease (COPD) overlap syndrome among COPD patients in Japan

Late-Breaker Poster Discussion Tuesday, 17 May, 2:15 PM-4:15 PM Abstract #A7889

Respiratory Biologics

 

Newbold P

High blood eosinophil concentrations and serum biomarkers of low IL-13 pathway activation at baseline predict exacerbation rate reduction by benralizumab for patients with moderate to severe asthma

Monday, 16 May, 2:15 PM Abstract #A4351

Ranade K

Dipeptidyl peptidase 4 (DPP4) is a novel predictive biomarker for the investigational anti-IL13 targeted therapy tralokinumab


Monday, 16 May, 2:15 PM Abstract #A4332

Eklira (aclidinium)

 

Beier J

Improvement in lung function and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post-hoc analysis of a Phase IIIb study


Wednesday, 18 May 9:00 AM Abstract #6817

Magnussen H

The effect of aclidinium bromide 400 µg on lung function, sleep quality and physical activity in patients with chronic obstructive pulmonary disease: Results of a Phase IV pilot study

Wednesday, 18 May 9:00 AM Abstract #6820

Duaklir (aclidinium/formoterol)

 

Miravitilles M

Efficacy of aclidinium/formoterol on bronchodilation and symptoms in symptomatic and asymptomatic patients with COPD: pooled analysis of two Phase III studies


Wednesday, 18 May 9:00 AM Abstract #6773

Singh D

Reduction in clinically important deterioration in chronic obstructive pulmonary disease in patients treated with aclidinium/formoterol combination

Wednesday, 18 May 9:00 AM Abstract #A6771

Daliresp/Daxas (roflumilast)

 

TREAT Mackay AJ

Roflumilast initiated at onset of acute exacerbation of COPD enhances lung function recovery: results from the randomised, double-blind, placebo-controlled, parallel-group trial, Treatment with Roflumilast at ExAcerbaTion (TREAT)


Tuesday, 17 May 9:00 AM Abstract #A5180

TREAT

Mackay AJ

Reduction of airway inflammation with roflumilast initiated at onset of acute exacerbation of COPD: results from the randomised, double-blind, placebo-controlled, parallel-group trial, Treatment with Roflumilast at ExAcerbaTion (TREAT)

Tuesday, 17 May 9:00 AM Abstract #A5181

Emerging and Disease Modification Science

 

Mardh CK

A novel inhaled non-steroidal modulator of inflammation for the control of asthma; AZD7594

Sunday, 15 May, 9:00 AM Abstract #A1329

Jackson S

Safety and tolerability of AZD1419, an inhaled oligonucleotide-based toll-like receptor 9 agonist in healthy volunteers: a potential new therapy for asthma

Sunday, 15 May, 9:00 AM Abstract #A1326

Goransson M

SIK inhibition: A novel opportunity to modulate disease phenotype in COPD

Tuesday, 17 May, 9:00 AM Abstract #5837

About Asthma

Asthma is a common, chronic condition in which inflammation and narrowing of the airways may cause wheezing, breathlessness, chest tightness and coughing. Despite current and available treatment options, asthma continues to effect the health and day-to-day lifestyles of more than 300 million children, men and women worldwide. By 2020, asthma will likely increase in numbers to affect as many as 400 million people.

Approximately 10% of asthma is severe, of which a reported 40% is uncontrolled. Severe, uncontrolled asthma has eight times higher risk of mortality. Uncontrolled asthma can lead to a dependence on oral corticosteroids (OCS). Systemic steroid exposure leads to serious & irreversible adverse effects, including osteoporosis, anxiety, depression, weight gain, glaucoma and diabetes. There is also a significant physical and socio-economic burden of asthma with 10% of severe patients accounting for 50% of asthma related health costs.

About COPD

COPD (chronic obstructive pulmonary disease) is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 329 million people worldwide and is predicted to be the third leading cause of death by 2030. Improving lung function and managing daily symptoms such as breathlessness are important to the management of COPD. It is estimated that eight out of 10 patients suffer symptoms at night, such as an irritative cough and difficulty breathing, frequent nocturnal awakenings, which leads to insomnia, worry and anxiety.

About Respiratory, Inflammation and Autoimmunity Diseases

Respiratory, Inflammation and Autoimmunity (RIA) is one of AstraZeneca’s main therapy areas, and we have a growing portfolio of medicines that reached more than 17 million patients in 2015. Our strong pipeline has the potential to deliver up to seven launches between 2016 and 2020. In respiratory disease, our aim is to transform asthma and COPD treatment through inhaled combinations at the core of care; precision biologics for the unmet needs of specific patient populations, and scientific advancements in disease modification. We are building on a 40-year heritage in respiratory disease, and our capability in inhalation technology spans both pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs), as well as our unique Co-Suspension Technology.

In Inflammation and Autoimmunity, our aim is to develop innovative therapies for the treatment of autoimmune and rheumatoid diseases, with a lead programme in systemic lupus erythematosus. Across respiratory, inflammation and autoimmune diseases, our research is focused on four key biological pathways: eosinophilic disease, Th2-driven disease, epithelial-driven pathobiology, and autoimmunity.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

CONTACTS

 

Media Enquiries

 

 

 

 

Neil Burrows

UK/Global

+44 20 7604 8032

Vanessa Rhodes

UK/Global

+44 20 7604 8037

Karen Birmingham

UK/Global

+44 20 7604 8120

Jacob Lund

Sweden

+46 8 553 260 20

Abigail Bozarth

US

+1 302 885 2677

 

 

 

 

Investor Enquiries

 

 

     

UK

 

 

Thomas Kudsk Larsen

Oncology

+44 7818 524185

Eugenia Litz

RIA

+44 7884 735627

Nick Stone

CVMD

+44 7717 618834

Henry Wheeler

Oncology

+44 7788 354619

Craig Marks

Finance

+44 7881 615764

Christer Gruvris

Consensus Forecasts

+44 7827 836825

 

 

 

 

US

 

 

Lindsey Trickett

Oncology, ING

+1 240 543 7970

Mitch Chan

Oncology

+1 240 477 3771

Dial / Toll-Free

 

+1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal

tags

  • Andningsvägar
  • Forskning och utveckling